Epivir-hbv

Discontinuation of anti-HBV therapy may be associated with severe acute exacerbations of hepatitis B. Closely monitor for several months after stopping treatment; if appropriate, anti-HBV therapy may be warranted. Not for treatment of HIV/HBV co-infection (use doses appropriate for HIV). Risk of HIV-1 resistance in patients with unrecognized or untreated HIV-1 infection; do HIV testing and counseling before and periodically during treatment. Emergence of resistance-associated HBV substitutions: monitor ALT and HBV DNA levels during treatment; consider alternative regimen if serum HBV DNA remains detectable after 24wks of treatment. Suspend if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Diabetes (oral soln). Liver transplant recipient, chronic HBV with decompensated liver disease, HCV or hepatitis delta virus co-infection: not established. Women. Obesity. Pregnancy. Nursing mothers.